It’s complicated and high risk but the rewards can be worth it. Investing in biotech isn’t for everyone, but there is a “sweet spot” for those who want to take the plunge, says Dominik Escher of Swiss-based Pureos Bioventures.
It’s complicated and high risk but the rewards can be worth it. Investing in biotech isn’t for everyone, but there is a “sweet spot” for those who want to take the plunge, says Dominik Escher of Swiss-based Pureos Bioventures.